Q1 EPS Estimates for Sutro Biopharma Raised by HC Wainwright

Sutro Biopharma, Inc. (NASDAQ:STRO) – Research analysts at HC Wainwright raised their Q1 2025 EPS estimates for shares of Sutro Biopharma in a note issued to investors on Monday, March 17th. HC Wainwright analyst A. Fein now anticipates that the company will post earnings per share of ($0.38) for the quarter, up from their prior forecast of ($0.82). HC Wainwright currently has a “Neutral” rating and a $2.00 price objective on the stock. The consensus estimate for Sutro Biopharma’s current full-year earnings is ($2.92) per share. HC Wainwright also issued estimates for Sutro Biopharma’s Q2 2025 earnings at ($0.41) EPS, Q3 2025 earnings at ($0.43) EPS, Q4 2025 earnings at ($0.46) EPS, FY2025 earnings at ($1.68) EPS, FY2026 earnings at ($0.20) EPS, FY2027 earnings at ($0.17) EPS, FY2028 earnings at ($0.13) EPS and FY2029 earnings at ($0.09) EPS.

A number of other analysts have also recently issued reports on STRO. Wedbush cut shares of Sutro Biopharma from an “outperform” rating to a “neutral” rating and reduced their target price for the company from $8.00 to $2.00 in a research note on Friday, March 14th. Wells Fargo & Company decreased their price objective on shares of Sutro Biopharma from $5.00 to $4.00 and set an “equal weight” rating for the company in a report on Wednesday, December 11th. Piper Sandler set a $2.00 target price on Sutro Biopharma in a report on Friday. Bank of America downgraded Sutro Biopharma from a “buy” rating to an “underperform” rating and decreased their price target for the stock from $11.00 to $1.00 in a research note on Friday, March 14th. Finally, JMP Securities reissued a “market outperform” rating and issued a $17.00 price objective on shares of Sutro Biopharma in a research note on Wednesday, December 11th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and three have given a buy rating to the company. According to data from MarketBeat, Sutro Biopharma has an average rating of “Hold” and an average target price of $6.63.

Sutro Biopharma Price Performance

Shares of Sutro Biopharma stock opened at $0.90 on Wednesday. The stock has a 50-day simple moving average of $1.71 and a 200-day simple moving average of $2.67. Sutro Biopharma has a 52-week low of $0.76 and a 52-week high of $6.13. The firm has a market cap of $73.89 million, a price-to-earnings ratio of -0.56 and a beta of 1.22.

Sutro Biopharma (NASDAQ:STRO) last issued its earnings results on Thursday, March 13th. The company reported ($2.96) EPS for the quarter, missing analysts’ consensus estimates of ($0.86) by ($2.10). Sutro Biopharma had a negative net margin of 77.01% and a negative return on equity of 101.89%. The firm had revenue of $14.00 million during the quarter, compared to analysts’ expectations of $10.44 million. During the same quarter last year, the firm earned ($1.78) EPS.

Institutional Trading of Sutro Biopharma

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in STRO. Connor Clark & Lunn Investment Management Ltd. acquired a new position in shares of Sutro Biopharma during the third quarter worth approximately $1,512,000. Intech Investment Management LLC bought a new position in Sutro Biopharma during the third quarter worth $91,000. Charles Schwab Investment Management Inc. raised its stake in Sutro Biopharma by 16.2% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 251,995 shares of the company’s stock valued at $872,000 after purchasing an additional 35,167 shares during the last quarter. Bank of Montreal Can bought a new stake in Sutro Biopharma in the 3rd quarter valued at $2,852,000. Finally, FMR LLC grew its position in Sutro Biopharma by 24.9% in the 3rd quarter. FMR LLC now owns 189,041 shares of the company’s stock worth $654,000 after purchasing an additional 37,701 shares during the last quarter. Institutional investors and hedge funds own 96.99% of the company’s stock.

Sutro Biopharma Company Profile

Sutro Biopharma, Inc operates as a clinical-stage oncology company. The company develops site-specific and novel-format antibody drug conjugates (ADCs) that enables its proprietary integrated cell-free protein synthesis platform, XpressCF and XpressCF+. Its product candidates include STRO-002, an ADC directed against folate receptor-alpha, which is in Phase II/III clinical trials for patients with ovarian and endometrial cancers; VAX-24 and Vax-31 pneumococcal conjugate vaccine candidates that is in Phase II/III clinical trials for the treatment of invasive pneumococcal disease; and MK-1484, a distinct cytokine derivative molecule that is in Phase I clinical study for the treatment of cancer.